We have also shown that the sensitizing activity of immune-modulatory agents, such as the αnti-CD20 monoclonal antibodies (mAbs) Rituximab, LFB-603, and BM-ca, on B-cell Non-Hodgkins lymphoma (B-NHL) cell lines resistant to TRAIL/FasL- and natural killer (NK)-induced apoptosis also involved Ab-mediated YY1 inhibition [74,183,188,189]. This evidence concerns the gene YY1 and non-Hodgkin lymphoma.